Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study
This longitudinal field study (n=242) assessed personality, mental health, life attitudes, and neuropsychological performance in a large number of long-term ritual ayahuasca users and control participants that were matched for age, sex, educational level, and religious background. Long-term ayahuasca use indicated a lower presence of psychopathological symptoms, better performance in neuropsychological tests, higher degrees of spirituality, and better psychosocial adaptation as reflected by some attitudinal traits such as Purpose in Life and Subjective Well-Being, and benefits on mental health were still observable in a one-year follow-up.
Authors
- Jordi Riba
- Draulio Araújo
- Maria Barbanoj
Published
Abstract
Introduction
Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT2A agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting alkaloids (harmine, harmaline and tetrahydroharmine) that render it orally active. Ayahuasca ingestion is a central feature in several Brazilian syncretic churches that have expanded their activities to urban Brazil, Europe and North America. Members of these groups typically ingest ayahuasca at least twice per month. Prior research has shown that acute ayahuasca increases blood flow in prefrontal and temporal brain regions and that it elicits intense modifications in thought processes, perception and emotion. However, regular ayahuasca use does not seem to induce the pattern of addiction-related problems that characterize drugs of abuse.
Methods
To study the impact of repeated ayahuasca use on general psychological well-being, mental health and cognition, here we assessed personality, psychopathology, life attitudes and neuropsychological performance in regular ayahuasca users (n = 127) and controls (n = 115) at baseline and 1 year later. Controls were actively participating in non-ayahuasca religions.
Results
Users showed higher Reward Dependence and Self-Transcendence and lower Harm Avoidance and Self-Directedness. They scored significantly lower on all psychopathology measures, showed better performance on the Stroop test, the Wisconsin Card Sorting Test and the Letter-Number Sequencing task from the WAIS-III, and better scores on the Frontal Systems Behavior Scale. Analysis of life attitudes showed higher scores on the Spiritual Orientation Inventory, the Purpose in Life Test and the Psychosocial Well-Being test. Despite the lower number of participants available at follow-up, overall differences with controls were maintained one year later.
Discussion
In conclusion, we found no evidence of psychological maladjustment, mental health deterioration or cognitive impairment in the ayahuasca-using group.
Research Summary of 'Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study'
Introduction
Ayahuasca is a traditional Amazonian psychoactive brew containing N,N-dimethyltryptamine (DMT) together with monoamine-oxidase inhibiting harmala alkaloids, which make DMT orally active. Acute administration produces marked alterations in perception, thought and emotion and increases blood flow in frontal and paralimbic brain regions, but prior neuroimaging did not show activation of classic reward structures implicated in addiction. Although previous, generally small studies have not detected clear long-term neuropsychological or psychopathological harm in ritual ayahuasca users, rising numbers of regular users and public health concerns motivate a more systematic evaluation of personality, mental health, life attitudes and cognitive function in long-term ritual contexts. Bouso and colleagues set out to examine these domains in a comparatively large sample of ritual ayahuasca users and matched non-using controls, with assessments at baseline and approximately one year later. The study aimed to determine whether long-term, regular ritual use is associated with maladaptive personality traits, increased psychopathology, or cognitive deficits, and to assess measures of spirituality and psychosocial well-being in this population.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., & Riba, J. (2012). Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study. PLoS ONE, 7(8), e42421. https://doi.org/10.1371/journal.pone.0042421
References (14)
Papers cited by this study that are also in Blossom
McKenna, D. · ACS Chemical Neuroscience (2004)
Fantegrossi, W. E., Murnane, K. S., Reissig, C. J. · Biochemical Pharmacology (2007)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)
Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)
Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)
De Araujo, D. B., Ribeiro, S., Cecchi, G. A. et al. · Human Brain Mapping (2011)
Doering-Silveira, E., Lopez, E., Grob, C. S. et al. · Journal of Psychoactive Drugs (2005)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
Show all 14 referencesShow fewer
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Halpern, J. H., Sherwood, A. R., Hudson, J. I. et al. · Biological Psychiatry (2005)
Santos, R. G., Landeira-Fernandez, J., Strassman, R. J. et al. · Journal of Ethnopharmacology (2007)
Trichter, S., Klimo, J., Krippner, S. · Journal of Psychoactive Drugs (2009)
Cited By (110)
Papers in Blossom that reference this study
Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)
Rego Ramos, L., Fernandes Jr, O., Arruda Sanchez, T. · Journal of Magnetic Resonance Imaging (2025)
Aicher, H. D., Wicki, I. A., Meling, D. et al. · Journal of Psychopharmacology (2025)
Pagni, B. A., Halman, A., Sarris, J. et al. · Journal of Psychoactive Drugs (2025)
Godfrey, K., Weiss, B., Zhang, X. et al. · Neuroscience Applied (2025)
Doss, M. K., Kloft, L., Mason, N. L. et al. · Journal of Psychopharmacology (2024)
Fonseca, A. M., Dos Santos, R. G., Santos, F. P. et al. · European Archives of Psychiatry and Clinical Neuroscience (2024)
Cassidy, K., Healy, C. J., Henje, E. et al. · Drug Science Policy and Law (2024)
Barnett, B. S., Arakelian, M., Beebe, D. et al. · Psychedelic Medicine (2024)
Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Humanistic Psychology (2024)
Show all 110 papersShow fewer
Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)
Cruz, L., Tófoli, L.F., Araújo, D. B. et al. · Scientific Reports (2023)
Jacobs, E., Murphy-Beiner, A., Rouiller, I. et al. · Neuroethics (2023)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · Frontiers in Neuroscience (2023)
Apud, I., Scuro, J., Rodríguez, L. et al. · Journal of Psychoactive Drugs (2023)
Bouso, J. C., Révész, D., Ona, G. et al. · Scientific Reports (2023)
Dinkelacker, J., Pop, I. · Journal of Clinical Psychiatry (2023)
Rossi, G. N., Rocha, J. M., Osório, F. L. et al. · Journal of Clinical Psychopharmacology (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Perkins, D., Ruffell, S. G. D., day, K. et al. · Frontiers in Neuroscience (2023)
Bouso, J. C., Andión, O., Sarris, J. et al. · PLOS Global Public Health (2022)
Guss, J. · Psychoanalytic Dialogues (2022)
Galvão-Coelho, N. L., De Meiroz Grilo, M. L. P., de Sousa, G. M. et al. · Frontiers in Behavioural Neuroscience (2022)
Perkins, D., Pagni, B. A., Sarris, J. et al. · Frontiers in Pharmacology (2022)
Bouso, J. C., Simonsson, O., Kurth, F. et al. · Frontiers in Psychiatry (2022)
Ornelas, I. M., Cini, F. A., Wießner, I. et al. · Experimental Neurology (2022)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Costa, M. A. · Journal of Psychoactive Drugs (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Kohek, M., Ona, G., Dos Santos, R. G. et al. · Journal of Psychoactive Drugs (2022)
Wießner, I., Olivieri, R., Falchi, M. et al. · European Neuropsychopharmacology (2022)
Orłowski, P., Ruban, A., Szczypiński, J. et al. · Journal of Psychopharmacology (2022)
Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)
Ramaekers, J. G. · Psychopharmacology (2022)
Almeida, C. A. F., Pereira, B. P., Pereira Junior, A. A. et al. · Behavioural Brain Research (2022)
Ona, G., Berrada, A., Bouso, J. C. · Transcultural Psychiatry (2021)
van Oorsouw, K., Uthaug, M. V., Mason, N. L. et al. · Journal of Psychedelic Studies (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Basedow, L. A., Riemer, T. G., Reiche, S. et al. · Frontiers in Pharmacology (2021)
Kuiperes, Z., Schreiber, R. · Neurobiology of Learning and Memory (2021)
Dos Santos, R. G., Rocha, J. M., Rossi, G. N. et al. · Frontiers in Psychiatry (2021)
Perkins, D., Opaleye, E. S., Simonová, H. et al. · Drug and Alcohol Review (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Bouso, J. C., Révész, D., Ona, G. et al. · Frontiers in Psychiatry (2021)
Rush, B., Marcus, O., García, S. et al. · Frontiers in Pharmacology (2021)
González, D., Cantillo, J., Perez, I. et al. · Frontiers in Pharmacology (2021)
Bathje, G. J., Fenton, J., Pillersdorf, D. et al. · Journal of Humanistic Psychology (2021)
Perkins, D., Schubert, V., Simonová, H. et al. · Frontiers in Pharmacology (2021)
Gard, D. E., Pleet, M. M., Bradley, E. R. et al. · Journal of Affective Disorders (2021)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)
O'shaughnessy, D. M., Berlowitz, I., Rodd, R. et al. · Therapeutic Advances in Psychopharmacology (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)
Johnstad, P. G. · Journal of Psychoactive Drugs (2020)
Aday, J. S., Davoli, C. C., Bloesch, E. K. · Therapeutic Advances in Psychopharmacology (2020)
Netzband, N., Ruffell, S., Linton, &. S. et al. · Psychopharmacology (2020)
Kangaslampi, S., Hausen, A., Rauteenmaa, T. · Journal of Psychoactive Drugs (2020)
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G. et al. · Scientific Reports (2020)
Murphy-Beiner, A., Soar, K. · Psychopharmacology (2020)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Kettner, H., Gandy, S., Haijen, E. C. H. M. et al. · International Journal of Environmental Research and Public Health (2019)
Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Cameron, L. P., Benson, C. J., Defelice, B. C. et al. · ACS Chemical Neuroscience (2019)
Mason, N. L., Mischler, E., Uthaug, M. V. et al. · Journal of Psychoactive Drugs (2019)
Ona, G., Kohek, M., Massaguer, T. et al. · Journal of Psychoactive Drugs (2019)
Stenbæk, D. S., Kristiansen, S., Burmester, D. et al. · Human Brain Mapping (2019)
Mello, S. M., Soubhia, P. C., Silveira, G. et al. · Journal of Psychoactive Drugs (2018)
Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)
Cameron, L. P. · ACS Chemical Neuroscience (2018)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Cameron, L. P., Benson, C. J., Dunlap, L. E. · ACS Chemical Neuroscience (2018)
Adams, T. · Biorxiv (2018)
Lawn, W., Hallak, J. E., Crippa, J. A. et al. · Scientific Reports (2017)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Stroud, J., Freeman, T. P., Leech, R. et al. · Psychopharmacology (2017)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
González, D., Carvalho, M., Aixalá, M. et al. · OMEGA - Journal of Death and Dying (2017)
Liechti, M. E. · Neuropsychopharmacology (2017)
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Apud, I., Romaní, O. · International Journal of Drug Policy (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Dos Santos, R. G., Hallak, J. E. · Journal of Psychoactive Drugs (2016)
Barbosa, P., Strassman, R. J., da Silveira, D. X. et al. · Comprehensive Psychiatry (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Dos Santos, R. G., Balthazar, F. M., Bouso, J. C. et al. · Journal of Psychopharmacology (2016)
Nunes, A. A., Dos Santos, R. G., Osório, F. L. et al. · Journal of Psychoactive Drugs (2016)
Nichols, D. E. · Pharmacological Reviews (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Favaro, V. M., Yonamine, M., Soares, J. C. K. et al. · PLOS ONE (2015)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Tupper, K. W., Wood, E., Yensen, R. et al. · Canadian Medical Association Journal (2015)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Dos Santos, R. G. · Journal of Psychoactive Drugs (2014)
Tracy, D., Baumeister, D., Barnes, G. et al. · Therapeutic Advances in Psychopharmacology (2014)
Winkler, P., Csémy, L. · Journal of Psychoactive Drugs (2014)
Loizaga-Velder, A., Verres, R. · Journal of Psychoactive Drugs (2014)
Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M. et al. · Psychopharmacology (2013)
Dos Santos, R. G. · Journal of Psychoactive Drugs (2013)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.